Skip to Content
Merck

O1141

Olanzapine

≥98% (HPLC), 5-HT2 serotonin and D1/D2 dopamine receptor antagonist, powder

Synonym(s):

LY-170053, 2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H20N4S
CAS Number:
132539-06-1
Molecular Weight:
312.43
NACRES:
NA.77
PubChem Substance ID:
329818894
UNSPSC Code:
12352200
MDL number:
MFCD00866702
Beilstein/REAXYS Number:
7655141
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Olanzapine, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

yellow

solubility

DMSO: >15 mg/mL

originator

Eli Lilly

storage temp.

2-8°C

SMILES string

CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24

InChI

1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

InChI key

KVWDHTXUZHCGIO-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813), DRD3(1814), DRD4(1815), HTR2A(3356), HTR2C(3358)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Olanzapine is a 5-HT2 serotonin and D1/D2 dopamine receptor antagonist.

Features and Benefits

This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Central nervous system

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000494864
0000494864
0000388589
0000294569
0000388589

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

N A Moore et al.
The Journal of pharmacology and experimental therapeutics, 262(2), 545-551 (1992-08-01)
Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine) is a novel "atypical" antipsychotic agent with 5-hydroxytryptamine2.dopamine D1/D2 antagonist activity and anticholinergic properties. In behavioral studies, olanzapine (1.25-10 mg/kg, p.o.) antagonizes apomorphine-induced climbing behavior in mice, demonstrating that the compound possesses D1/D2 antagonist activity in
Stephen M Stahl et al.
The Journal of clinical psychiatry, 74(5), 507-515 (2013-04-02)
The primary objective was to evaluate the safety and tolerability of lurasidone, a new atypical antipsychotic agent, in the longer-term treatment of schizophrenia (DSM-IV). Persistence of symptom improvement was assessed as a secondary outcome. Patients who completed a 6-week, double-blind
Gabriele Sani et al.
Journal of clinical psychopharmacology, 33(2), 231-235 (2013-02-21)
Prognosis of comorbid bipolar disorder (BD) and drug abuse is poor. We assessed the efficacy of olanzapine in manic or mixed BD patients, with (SUD) or without (N-SUD) comorbidity with substance use disorder (SUD) and its effect on drug abuse
Heating under high-frequency inductive conditions: application to the continuous synthesis of the neurolepticum olanzapine (Zyprexa).
Jan Hartwig et al.
Angewandte Chemie (International ed. in English), 52(37), 9813-9817 (2013-07-31)
Joseph P McEvoy et al.
The Journal of clinical psychiatry, 74(2), 170-179 (2013-03-12)
To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies. Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidone dosing regimens for the initial 2
View All Related Papers

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service